PharmaBlock Sciences Nanjing Inc Class A (300725) — Net Asset Quality Index
PharmaBlock Sciences Nanjing Inc Class A (300725) has a Net Asset Quality Index of 91.7% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥7.79 Billion minus total liabilities of CN¥645.64 Million yields net assets of CN¥7.15 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See PharmaBlock Sciences Nanjing Inc Class A liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
PharmaBlock Sciences Nanjing Inc Class A Net Asset Quality Index Over Time (2013–2024)
This chart shows how PharmaBlock Sciences Nanjing Inc Class A's Net Asset Quality Index has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the index stands at 91.7%, representing net assets of CN¥7.15 Billion against total assets of CN¥7.79 Billion CNY. Explore 300725 cash generation efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for PharmaBlock Sciences Nanjing Inc Class A (2013–2024)
The table below presents the year-by-year Net Asset Quality Index for PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2024, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see PharmaBlock Sciences Nanjing Inc Class A market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 60.5% | CN¥2.99 Billion | CN¥4.94 Billion | CN¥1.95 Billion | ▲ +5.0 pp |
| 2023 | 55.5% | CN¥2.83 Billion | CN¥5.10 Billion | CN¥2.27 Billion | ▲ +0.8 pp |
| 2022 | 54.7% | CN¥2.66 Billion | CN¥4.86 Billion | CN¥2.20 Billion | ▼ -20.3 pp |
| 2021 | 74.9% | CN¥2.63 Billion | CN¥3.51 Billion | CN¥879.21 Million | ▼ -3.2 pp |
| 2020 | 78.1% | CN¥1.89 Billion | CN¥2.43 Billion | CN¥530.57 Million | ▲ +6.1 pp |
| 2019 | 72.0% | CN¥740.87 Million | CN¥1.03 Billion | CN¥288.27 Million | ▼ -6.8 pp |
| 2018 | 78.8% | CN¥599.73 Million | CN¥761.16 Million | CN¥161.43 Million | ▼ -10.0 pp |
| 2017 | 88.8% | CN¥503.59 Million | CN¥567.40 Million | CN¥63.80 Million | ▲ +3.8 pp |
| 2016 | 85.0% | CN¥254.15 Million | CN¥299.15 Million | CN¥45.00 Million | ▼ 0.0 pp |
| 2015 | 85.0% | CN¥146.56 Million | CN¥172.48 Million | CN¥25.92 Million | ▼ -0.9 pp |
| 2014 | 85.8% | CN¥87.18 Million | CN¥101.56 Million | CN¥14.38 Million | ▲ +3.4 pp |
| 2013 | 82.4% | CN¥70.16 Million | CN¥85.13 Million | CN¥14.97 Million | — |